Incyte reported higher third-quarter revenue and product sales, led by continued growth in Opzelura and its hematology and oncology portfolio alongside a smaller increase in Jakafi. The company also raised its 2026 sales guidance for Opzelura, hematology and oncology, and total net sales, and outlined clinical programs it expects to advance.
Key details
-
Revenue and sales rose 14% year over year. Incyte reported third-quarter revenue of $1.56 billion and total net sales of $1.32 billion. It attributed the sales increase to stronger demand across marketed products.
-
Jakafi remained the largest product, but grew more slowly. Sales of Jakafi and Jakafi XR reached $827 million, up 4% from a year earlier.
-
Opzelura and the hematology and oncology portfolio grew faster. Opzelura cream sales were $255 million, up 36%. Hematology and oncology portfolio sales were $235 million, up 38%.
-
The company raised full-year 2026 sales guidance for Opzelura, hematology and oncology, and total net sales. The announcement provided no revised guidance figures in the material supplied.
-
Incyte is expanding its gastrointestinal cancer pipeline. Phase 1 data for INCB161734 and INCA033890 support the company’s development strategy in gastrointestinal cancers, with multiple registrational studies planned or underway in 2027. Incyte’s CEO highlighted a KRAS G12D inhibitor for pancreatic and colorectal cancers and a TGFβR2×PD-1 bispecific antibody for colorectal cancer as pipeline priorities.
-
Several blood-disease programs are moving toward or into pivotal testing. Phase 3 studies are underway or planned for INCA033989 in essential thrombocythemia and myelofibrosis, and for latarcibart in von Willebrand disease. Incyte described its CALR-targeted antibody and Protein S modulator as important programs in these areas.
-
Two other Phase 3 readouts are expected by year-end: povorcitinib for prurigo nodularis and ruxolitinib cream for hidradenitis suppurativa.
What it means
Jakafi generated about 63% of the quarter’s $1.32 billion in net sales, while Opzelura and the hematology and oncology portfolio together contributed about $490 million. The faster growth in those businesses shows that sales outside Jakafi are becoming a larger part of Incyte’s commercial base. The company also pointed to its advancing clinical programs as potential sources of growth beyond 2029.